公司資料
DexCom, Inc. 股價、新聞與催化劑
- 股票代碼:
- DXCM
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
86.23 USD (-0.07%)
收盤價
最後更新: 2026年10月1日
28.3B USD
市值
股價為何變動
截至 2026年10月1日，DXCM 股價變化不大，收於 $86.23。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Glucose Biosensing Company
Dexcom develops continuous glucose monitoring systems that help people measure and manage glucose without relying only on intermittent finger-stick tests. Its products serve people with diabetes as well as consumers seeking broader metabolic-health insights.
Prescription CGM Franchise
The Dexcom G7 platform provides real-time glucose readings, alerts, trend information, and connectivity to compatible mobile devices and insulin-delivery systems. The franchise is used across intensive insulin therapy, basal insulin, and expanding populations with type 2 diabetes.
Stelo Consumer Platform
Stelo is an over-the-counter glucose biosensor and app designed for adults who do not use insulin. It extends Dexcom into direct-to-consumer distribution and combines glucose data with food logging, behavioral insights, and AI-enabled interpretation.
Clinical Evidence and Market Expansion
Dexcom invests in randomized studies such as CONNECT to demonstrate the value of continuous glucose monitoring in less intensively treated populations. Evidence generation supports payer coverage, clinical guidelines, and adoption among primary-care clinicians and people with type 2 diabetes.
Connected Diabetes Ecosystem
The company integrates its sensors with insulin pumps, connected pens, digital health applications, and clinical data platforms. These partnerships make Dexcom's data a core component of automated insulin delivery and remote diabetes management.
未來催化劑
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。